Physician profile
David M Tarter
NPI 1407889371
$4,682.61
in general payments reported to CMS, 2019-2025
25 companies · $551 in 2025
The $551 reported for 2025 was more than what 91% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $257 · 2021: $745 · 2022: $994 · 2023: $614 · 2024: $784 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,947.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $793.00 | 2019-2025 | |
| Abbvie INC. | $779.02 | 2021-2025 | Dalvance |
| Novartis Pharmaceuticals Corporation | $708.26 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $511.01 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $327.48 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| E.R. Squibb & Sons, L.L.C. | $273.27 | 2019-2024 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.74 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.52 | 2020-2025 | Xifaxan |
| Gilead Sciences, INC. | $156.70 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $124.31 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $123.28 | 2019-2023 | Andexxa |
| Novo Nordisk INC | $70.53 | 2023-2024 | Ozempic, Rybelsus |
| Sk Life Science, INC. | $65.47 | 2025 | |
| Alexion Pharmaceuticals, INC. | $52.21 | 2024-2025 | Ultomiris |
| Boston Scientific Corporation | $44.49 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $44.23 | 2023 | Smartvest |
| Paratek Pharmaceuticals, INC. | $39.02 | 2022 | |
| Amgen INC. | $38.96 | 2019-2022 | |
| Philips North America LLC | $28.50 | 2021-2022 | |
| Lundbeck LLC | $24.32 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.14 | 2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $21.20 | 2024 | |
| Shire North American Group INC | $13.92 | 2019 | |
| Melinta Therapeutics, LLC | $13.61 | 2021 | |
| Sunovion Pharmaceuticals INC. | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tarter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.